PEPTIDES 47
eventually becomes visible at the skin surface, the skin gradually exhibits reduced smoothness, lower elasticity and diminished recovery capacity, contributing to wrinkle formation and a rougher, less homogeneous appearance. To investigate whether the structural
improvements observed ex vivo could translate into visible cosmetic benefits, the encapsulated EGF delivery system was further evaluated under clinical conditions through a 56-day half-face study under dermatological control with twice-daily topical application. One of the assessed parameters was
skin roughness using three-dimensional skin profilometry through the Ra parameter, which reflects overall surface irregularities and texture heterogeneity. Lower Ra values are associated with smoother and more homogeneous skin topography. After 56 days of twice-daily application, the
encapsulated EGF delivery system reduced skin roughness by 23% compared with baseline values and achieved a 1.4-fold greater improvement in skin smoothness versus untreated skin (Figure 3). These instrumental results suggest an overall improvement in surface organization and visible skin texture quality. Clinical imaging further supported these findings (Figure 4). VISIA® analysis revealed visible improvements in overall skin texture and wrinkle appearance after treatment, together with reduced surface irregularities and improved skin smoothness. Visible softening of the nasolabial fold as
well as reductions in marionette line depth and length were also observed throughout the treated areas. Horizontal reference lines were included to facilitate visual comparison between experimental time points. Volunteer perception additionally reinforced these observations, with 88% of participants reporting smoother skin and 92%
Day 0 Day 56
Figure 4: Representative VISIA images of the cheek area at baseline (D0) and after 56 days (D56) of treatment with the encapsulated EGF delivery system during a clinical study
perceiving firmer skin after 56 days of use. Wrinkle appearance was additionally
evaluated using the Rz parameter, which reflects wrinkle depth by measuring the average distance between peaks and valleys within the skin surface profile. Following 56 days of treatment, the encapsulated EGF system reduced wrinkle depth by 27% versus baseline and achieved a 1.9-fold greater wrinkle reduction compared with untreated skin (Figure 3). PRIMOS® analysis of the periocular area
further confirmed these effects, revealing visible reductions in wrinkle depth and wrinkle intensity within the crow’s feet region together with improvements in overall skin texture homogeneity and surface smoothness. VISIA images additionally showed visible
smoothing of the upper eyelid area together with reductions in wrinkle length and depth within crow’s feet, infraorbital and tear trough regions after treatment (Figure 5). These instrumental observations were
www.personalcaremagazine.com
July 2026 PERSONAL CARE MAGAZINE
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72
